Monitor for regulatory approval and closing timeline; the acquisition strengthens Fortrea's early-stage pipeline and could drive revenue growth from integrated Phase I-IV services. Watch for any integration risks or competitive responses from other CROs.
Price Chart
Executive Summary
Fortrea (FTRE) announced a definitive agreement to acquire Worldwide Clinical Trials' Early Phase Services division for approximately $45M in cash. The deal adds a GLP bioanalytical lab in Austin, a 200-bed clinical pharmacology unit in San Antonio, and a biospecimen storage facility, strengthening Fortrea's early-phase clinical development capabilities and end-to-end platform. The transaction is pending regulatory approvals and is expected to close with a strategic alliance agreement ensuring continuity for customers and employees.
Key Financial Metrics
Key Facts
- Fortrea acquires Worldwide Clinical Trials' Early Phase Services division for ~$45M all-cash.
- Assets include a 60,000 sq. ft. GLP bioanalytical lab in Austin, a 200-bed GCP-compliant CPU in San Antonio, and a biospecimen storage facility in Pflugerville, Texas.
- Acquisition enhances Fortrea's early-phase capabilities with in-house large and small molecule bioanalytical services and expands North American clinical research unit footprint.
- Transaction expected to close pending regulatory approvals and entry into services agreements; Barclays and Mintz Levin advising Fortrea.
- Worldwide will continue to support healthy volunteer studies globally via its external site network, focusing on late-stage growth in oncology, neuroscience, internal medicine, and rare disease.
Financial Impact
All-cash acquisition valued at approximately $45M, enhancing early-phase capabilities and capacity.
Risk Factors
- Regulatory approval delays or conditions could postpone closing.
- Integration challenges may disrupt operations or customer relationships.
- The $45M cash outlay reduces financial flexibility; debt or equity financing may be needed if additional acquisitions follow.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3354960 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Press Release | $23.63 $23.83 | ▲ +0.85% | ▲ +0.14% | $23.83 (+0.85%) |
Oct 19, 2026 7d ago | Press Release | $22.78 $24.06 | ▲ +5.62% | ▲ +5.09% | $23.83 (+4.61%) |
Oct 5, 2026 21d ago | Press Release | $21.11 $20.78 | ▼ −1.56% | ▼ −2.11% | $23.83 (+12.88%) |
Sep 30, 2026 26d ago | 8-K | $19.40 $20.00 | ▲ +3.09% | ▲ +2.35% | $23.83 (+22.84%) |
Sep 10, 2026 6w ago | Press Release | $17.20 $17.41 | ▲ +1.22% | ▲ +1.67% | $23.83 (+38.55%) |
Sep 10, 2026 6w ago | 8-K | $17.02 $17.20 | ▲ +1.06% | ▲ +0.21% | $23.83 (+40.01%) |
Sep 2, 2026 7w ago | Press Release | $18.36 $18.62 | ▲ +1.42% | ▲ +0.37% | $23.83 (+29.79%) |
Aug 22, 2026 9w ago | Institutional Cluster | $18.31 $18.27 | ▼ −0.22% | ▼ −0.54% | $23.83 (+30.15%) |
Aug 7, 2026 11w ago | Insider Cluster | $18.99 $19.52 | ▲ +2.79% | ▲ +3.11% | $23.83 (+25.49%) |
Aug 6, 2026 11w ago | Insider Cluster | $18.43 $18.99 | ▲ +3.04% | ▲ +3.07% | $23.83 (+29.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers